Richmond, BC — SignalChem Lifesciences Corp announced the publication of first-in-human Phase 1 clinical trial results for SLC-391, its novel, orally bioavailable and selective AXL inhibitor, in the peer-reviewed journal… Read More
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the potential of BGB-B2033 in an area… Read More
BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study FRANKLIN LAKES, NJ – BD (Becton,… Read More
Retrospective analysis at top-tier medical facility highlights AI solution’s ability to help spot previously missed cancers and correctly localize suspicious areas on mammograms MARLBOROUGH, Mass — Hologic, Inc , a… Read More
Wegovy® (semaglutide injection) granted conditional marketing authorization for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3… Read More
